English
  • Suzetrigine

    Suzetrigine

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Suzetrigine Analgesic Vertex Pharmaceuticals  Dec.4,2040
    inquirydetail
  • Orforglipron

    Orforglipron

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Orforglipron Type 2 Diabetes Eli Lilly and Company  Sep.26,2037
    inquirydetail
  • Osimertinib

    Osimertinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Osimertinib NSCLC AstraZeneca  Aug.8,2032
    inquirydetail
  • Alectinib

    Alectinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Alectinib NSCLC Roche Pharma AG  Jun. 9,2030
    inquirydetail
  • Zanubrutinib

    Zanubrutinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Zanubrutinib MCL/CLL/SLL/WM BeiGene  Apr.2034
    inquirydetail
  • Dabrafenib

    Dabrafenib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Dabrafenib  Melanoma  Novartis（GSK R&D）  Jul.20, 2030
    inquirydetail
  • Aprocitentan

    Aprocitentan

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Aprocitentan  hypertension  Idorsia Pharmaceuticals Deutschland GmbH  Sep. 21.2034
    inquirydetail
  • Etrasimod

    Etrasimod

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Etrasimod Ulceratuve Colitis(UC) Arena(Pfizer)  Mar.05,2030
    inquirydetail
  • Tirzepatide

    Tirzepatide

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Tirzepatide Type 2 diabetes, lose weight Eli Lilly  Jan.05,2036
    inquirydetail
  • Semaglutide

    Semaglutide

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Semaglutide Type2 diabetes,lose weight Novo Nordisk  Dec.05,2031
    inquirydetail
  • Oteseconazole

    Oteseconazole

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Oteseconazole Reduce the incidence rate of

    recurrent vulvovaginal candidiasis

    		 MycoviaPharmaceuticals  Apr.22,2031
    inquirydetail
  • Finerenone

    Finerenone

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Finerenone Diabetic Nephropathy Bayer  Apr.12,2029
    inquirydetail
123456 Next > >> Page 1 / 6